3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
20
Nasopharyngeal Carcinoma
8
Lung Neoplasms
7
Colorectal Neoplasms
4
Melanoma
3
Esophageal Squamous Cell Carcinoma
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Sarcoma
2
Osteosarcoma
2
Nasopharyngeal Neoplasms
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell
2
Esophageal Neoplasms
2
Unresectable Non-small Cell Lung Cancer
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Radiation Injuries
1
Quality of Life
1
Pleural Effusion, Malignant
1
Non-squamous Non-small Cell Lung Cancer
1
Neuroblastoma
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Esophageal
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Bone Neoplasms
1
Advanced Pancreatic Cancer
1
Interventions
Ibandronic Acid
8
Gemcitabine
8
Doxorubicin
6
Cyclophosphamide
6
Zoledronic Acid
5
Radiation
4
Nivolumab
4
Irinotecan
4
pembrolizumab
3
Vincristine
3
Temozolomide
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Docetaxel
3
Cisplatin
3
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
3
regorafenib
2
pegfilgrastim
2
Tranexamic Acid
2
Trabectedin
2
Sunitinib
2
Standard of Care
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiosurgery
2
Proton Therapy
2
Methotrexate
2
Injections
2
Ifosfamide
2
Etoposide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Bone Neoplasms
×
endostar protein
×
Clear all
NCT06562673
2025-12-29
IACE-OS
Shanghai 6th People's Hospital
Phase 1/2
Completed
10 enrolled